1- http://www.invs.sante.fr/surveillance/cancers/estimations_cancers/defau…
2- Matutes E., Owusu-Ankomah K., Morilla R., Garcia Marco J., Houlihan A., Que T.H., Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994 Oct ; 8 (10) : 1640-5
3- Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15 ; 111 (12) : 5446-56.
4- Leporrier M. Leucémie lymphoïde chronique. Rev Prat 2008 ; 58 :1861-1867.
5- Catovsky D., Richards S., Matutes E. et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group ; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial) : a randomised controlled trial. Lancet. 2007 Jul 21 ; 370 (9583) : 230-9.
6- Lozanski G., Heerema N.A., Flinn I.W. et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004 May 1;103(9) : 3278-81.
Mise au point
Les urgences psychiatriques en médecine générale
Étude et pratique
Mortalité liée au tabac, le sevrage bénéfique quel que soit l’âge
Cas clinique
Le kyste osseux anévrismal
Recommandation
Le RGO du nourrisson